Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics

The Institut Pasteur

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application PCT/EP2021/025053, filed Feb 12, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,948,490	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	Term ends Jul 23, 2040	High confidence
US 11,815,513	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	Term ends Jul 23, 2040	High confidence
US 12,326,451	Severe Acute Respiratory Syndrome (SARS) - Associated Coronavirus Diagnostics Institut Pasteur In force Term ends Jul 23, 2040 · High confidence	Institut Pasteur	In force	Term ends Jul 23, 2040	Term ends Jul 23, 2040	High confidence
US 11,759,516	NUCLEIC ACID VACCINE AGAINST THE SARS-CoV-2 CORONAVIRUS Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 11,911,462	Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 11,964,013	Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 11,969,467	Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 12,171,827	Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 12,324,834	Nucleic Acid Vaccine Against the SARS-COV-2 Coronavirus Institut Pasteur In force Term ends Feb 12, 2041 · High confidence	Institut Pasteur	In force	Term ends Feb 12, 2041	Term ends Feb 12, 2041	High confidence
US 12,136,181	Method for visualizing at least a zone of an object in at least one interface Institut Pasteur In force Term ends May 25, 2042 · High confidence	Institut Pasteur	In force	Term ends May 25, 2042	Term ends May 25, 2042	High confidence
6 more patents in this group · Pro

10 of 16 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 16.

Upgrade to Pro

10 of these are in force and held by The Institut Pasteur.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.